Concepedia
Statistics
Publications
32
Citations
3.4K
H-Index
20
Active since
2014
Affiliations
Vrije Universiteit Amsterdam(Current)
Amsterdam University Medical Centers
University Medical Center Groningen
St. Antonius Ziekenhuis
Erasmus MC Cancer Institute
Inger S. Nijhof is an author at Vrije Universiteit Amsterdam specializing in multiple myeloma, medicine, and immunotherapy.
Publications per year
2014–2025
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof et al. · Blood · 2016 · 918 citations · Full text
Life Sciences, Immunology, Oncology +17
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro et al. · New England Journal of Medicine · 2023 · 515 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +17
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen et al. · Blood · 2016 · 380 citations · Full text
Life Sciences, Immunology, Oncology +13
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
Inger S. Nijhof, Richard W.J. Groen, H M Lokhorst et al. · Leukemia · 2015 · 266 citations · Full text
Medicine, Immunology, Pharmacology +17
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Jakub Krejcik, Kris A. Frerichs, Inger S. Nijhof et al. · Clinical Cancer Research · 2017 · 171 citations
Medicine, Immunology, Pharmacology +15
1–5 of 32